Ketosis is a metabolic disorder frequently occurring in the perinatal period, characterized by elevated circulating concentrations of nonesterified fatty acids (NEFA) due to negative energy balance, resulting in fatty liver in dairy cows. However, the mechanism of hepatic steatosis induced by high concentrations of NEFA in ketosis remains unclear. Hypoxia-inducible factor 2α (HIF-2α), which mediates adaptation to hypoxic stress, plays a critical role in regulating lipid metabolism. In this study, we investigate whether HIF-2α is involved in NEFA-driven hepatic lipid accumulation in dairy cows with ketosis. Liver and blood samples were collected from 10 healthy cows (blood β-hydroxybutyrate (BHB) concentration <1.2 mM) and 10 ketotic cows (blood BHB concentration >3.0 mM with clinical symptoms) with similar lactation numbers (median = 3, range = 2 to 4) at 3 to 9 d in milk (median = 6). In cows with ketosis, serum concentrations of NEFA and β-hydroxybutyrate (BHB) were greater but serum concentrations of glucose were lower. Moreover, hepatic triglyceride content increased significantly. In the liver of ketotic cows, which was accompanied by upregulated HIF-2α expression. To determine the potential association among hypoxia, HIF-2α, and the formation of hepatocellular steatosis in vitro, we isolated hepatocytes from healthy calves for the following experiments. First, hepatocytes were treated with 0, 0.6, 1.2, or 2.4 mM NEFA (52.7 mM stock NEFA solution was diluted in RPMI-1640 basic medium supplemented with 2% fatty acid-free BSA to achieve the specified concentrations) for 18 h, showing that HIF-2α expression and cellular hypoxia occurred in a dose-dependent manner. Next, hepatocytes were infected with HIF-2α (encoded by EPAS1) small interfering RNA (Si-HIF-2α) for 48 h and then treated with 1.2 mM NEFA for 18 h. Results indicated that silencing HIF-2α decreased NEFA-induced lipid accumulation in bovine hepatocytes. Subsequently, hepatocytes treated with or without NEFA were placed in an AnaeroPack System, mimicking a hypoxic condition, for 0, 12, 18, or 24 h. Results showed that hypoxia could induce and further exacerbate lipid accumulation in bovine hepatocytes. Meanwhile, normal or NEFA-treated hepatocytes were cocultured with or without PT2385, a specific HIF-2α inhibitor, showing that hypoxia promoted steatosis through HIF-2α. Activating transcription factor 4 (ATF4) is an endoplasmic reticulum (ER) stress and hypoxia-inducible transcription factor. Here, bovine hepatocytes were treated with NEFA or hypoxia following transfecting ATF4 small interfering RNA (Si-ATF4), which demonstrated that ATF4 knockdown alleviated the extent of lipid accumulation in bovine hepatocytes. Besides, we found that ATF4 expression was correlated with HIF-2α levels in both liver tissue and cultured hepatocyte models. Moreover, overexpression of ATF4 weakened the beneficial effects of HIF-2α inhibition. Overall, these data suggest that NEFA-induced hepatic hypoxia significantly contributes to the progression of hepatic steatosis which in turn, intensifies hypoxia and leads to a self-perpetuating cycle of reciprocal causation, further exacerbating hepatic lipid deposition. Additionally, accumulated HIF-2α plays a critical role in this complex-origin steatosis, potentially through ATF4.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3168/jds.2024-25839 | DOI Listing |
Sci Adv
March 2025
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Carbohydrate-responsive element binding protein (ChREBP) and Max-like protein X (MLX) form a heterodimeric transcription factor complex that couples intracellular sugar levels to carbohydrate and lipid metabolism. To promote the expression of target genes, two ChREBP-MLX heterodimers form a heterotetramer to bind a tandem element with two adjacent E-boxes, called carbohydrate-responsive element (ChoRE). How the ChREBP-MLX hetero-tetramerization is achieved and regulated remains poorly understood.
View Article and Find Full Text PDFMycorrhiza
March 2025
INRAE, Institut Agro Dijon, Université de Bourgogne, Agroécologie, Dijon, France.
Plant-microorganism interactions underlie many ecosystem roles, in particular the enhancement of plant nutrition through mutualistic relationships, such as the arbuscular mycorrhizal symbiosis that affects a large proportion of land plants. The establishment of this interaction induces a wide range of signaling pathways in which lipids, and particularly sterols, may play a central role. However, their supported functions are poorly known.
View Article and Find Full Text PDFMetab Brain Dis
March 2025
Cardio/Endo-Metabolic and Epigenetics Research Unit, Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, 360101, Nigeria.
Background: Polycystic ovary syndrome (PCOS) is a common endocrinometabolic disorder affecting women of reproductive age, characterized by hormonal imbalances, irregular menstrual cycles, and often, infertility. Hypothalamic amenorrhea, a condition marked by the cessation of menstruation due to disruptions in the hypothalamic-pituitary-gonadal axis, is a frequent manifestation in PCOS. Probiotics, beneficial microorganisms known for improving metabolic health, have shown promise in restoring hormonal balance and enhancing fertility.
View Article and Find Full Text PDFNanomaterials (Basel)
February 2025
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
Acute myocardial infarction, a leading cause of death globally, is often associated with cardiometabolic disorders such as atherosclerosis and metabolic syndrome. Metabolic treatment of these disorders can improve cardiac outcomes, as exemplified by the GLP-1 agonist semaglutide. Fibroblast growth factor 21 (FGF21), a novel metabolic regulator, plays pivotal roles in lipid mobilization and energy conversion, reducing lipotoxicity, inflammation, mitochondrial health, and subsequent tissue damage in organs such as the liver, pancreas, and heart.
View Article and Find Full Text PDFAnn Pharmacother
March 2025
Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD).
Data Sources: A literature review was conducted using the search terms , , , , , and on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data.
Study Selection And Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!